Philadelphia Eagles quarterback Jalen Hurts has been ruled out of Sunday’s game against the Carolina Panthers due to a superficial blood clot in his calf, the team said Thursday. The condition, also known as superficial thrombophlebitis or superficial vein thrombosis, was discovered last week after an ultrasound performed out of an abundance of caution, and a follow-up scan this week showed movement in the small clot.
The Eagles detailed the timeline in a statement. Hurts was cleated in the calf during the Oct. 4 loss to the Los Angeles Rams. He first sought treatment after practice on Oct. 8, practiced fully that week, and was added to the injury report. An ultrasound in London on Oct. 10 after the team’s flight and walkthrough revealed the superficial blood clot. Medical staff and doctors in London concluded that activity and mobility were important and that Hurts could safely play against the Jacksonville Jaguars, with a recommended follow-up ultrasound within 72 hours of the game and the return flight to Philadelphia. Hurts played without limitation in the 19-17 loss to the Jaguars, completing 21 of 40 passes for 220 yards and a touchdown. He received treatment Monday and Tuesday, practiced fully Wednesday, and then underwent the follow-up ultrasound Wednesday night that showed movement in the clot. The team said it remained in communication with the league office throughout.
NFL Network’s Ian Rapoport reported that Hurts cannot play until the situation is resolved and is out indefinitely. Backup Tanner McKee is expected to start against the Panthers.
What a Superficial Blood Clot Means Medically
Superficial thrombophlebitis involves a blood clot and inflammation in veins close to the skin’s surface, typically in the arms or legs. It often produces localized pain, tenderness, warmth, redness or discoloration, and swelling. Unlike deep-vein thrombosis (DVT), which forms in deeper veins and carries a higher risk of pieces of the clot breaking off and traveling to the lungs as a pulmonary embolism, superficial clots are generally considered less dangerous. The Cleveland Clinic notes that the condition typically resolves within a few weeks with supportive care such as warm compresses, limb elevation, nonsteroidal anti-inflammatory drugs, and compression stockings when appropriate.
However, medical sources emphasize it is not always benign. Superficial vein thrombosis can coexist with or extend into the deep venous system, particularly if the clot is longer (often cited around 5 cm or more), involves larger superficial veins such as the great saphenous vein, or sits close to junctions with deep veins. Studies and guidelines have found concurrent DVT in a substantial minority of superficial thrombosis cases at diagnosis, and a risk of progression or thromboembolic complications in the weeks afterward. Mayo Clinic states that complications from isolated superficial thrombophlebitis are rare, but if it progresses to DVT the risks rise, including pulmonary embolism. Ultrasound is the standard tool to confirm the diagnosis, rule out deeper involvement, and monitor for change—the exact approach the Eagles have used.
Athletes face some elevated exposure because of trauma, dehydration, and periods of immobility during travel. A cleat strike can injure a vein wall and contribute to local clotting, consistent with the history the Eagles described.
Was It Dangerous to Let Him Play?
Doctors in London determined that Hurts could play, specifically noting that activity and mobility were important. In general, for small, isolated superficial clots away from deep junctions, continued mobility is often preferred over complete rest because prolonged immobility can itself promote clotting. The team’s statement frames the initial clearance as a medical judgment after reviewing the ultrasound, not a decision to play through a deep-vein clot or pulmonary embolism. Hurts then played without limitation and continued full practice participation until the next scan.
The subsequent finding of “movement” changed the picture. Public details do not specify the size of the clot, the exact vein involved, its proximity to deep veins, or whether any extension into the deep system has occurred. Movement can indicate the clot is not stable, is extending, or is changing in a way that raises concern for progression. The Eagles have not announced a diagnosis of DVT or pulmonary embolism. Former NFL team doctor David Chao and other observers have noted that the league was kept informed, underscoring the seriousness with which the situation is being treated even for a superficial clot.
Current Risks and What Comes Next
The immediate priority is determining whether the clot remains purely superficial or has progressed. Risks include extension into deeper veins, the formation of additional clots, and—in the worst case—embolization to the lungs. Symptoms that would require emergency care include sudden shortness of breath, chest pain, coughing up blood, or significant new swelling and pain in the leg.
Treatment will dictate the timeline and contact risk. Smaller, uncomplicated superficial clots are often managed with anti-inflammatory measures and monitoring, resolving in weeks. Larger clots or those near deep-vein junctions frequently warrant a course of anticoagulation (blood thinners), commonly around 45 days under current guidelines, to reduce the chance of extension or embolism. If Hurts is placed on anticoagulants, the bleeding risk becomes relevant in a contact sport: collisions can produce internal or intracranial bleeding that would not occur at the same rate off the medication. Many athletes return after treatment for venous thromboembolism, but clearance for full contact is individualized and typically requires resolution of the acute clot, completion or adjustment of therapy, and shared decision-making among the player, team physicians, and specialists.
The Eagles have said they are determining the appropriate course of treatment and that Hurts’ health and safety are the highest priority. No firm return date has been given. Additional imaging and the decision on anticoagulation will clarify whether this remains a short-term absence measured in days to a few weeks or something longer. Until the situation is resolved, as Rapoport reported, Hurts will not play.
The distinction between superficial and deep clots matters, but “movement” after an initial clearance means the medical staff is treating the case with caution rather than assuming it will simply resolve while Hurts continues full football activity.
